



## **TO THE COMISIÓN NACIONAL DEL MERCADO DE VALORES**

**SACYR, S.A. ("Sacyr")**, pursuant to applicable laws and regulations, discloses the following:

### **OTHER RELEVANT INFORMATION**

Sacyr has resolved to commence execution of the capital increase charged to profit or reserves (scrip dividend) adopted by resolution of the ordinary general meeting of shareholders held on 12 June 2026, at second call, under item twelfth, of the agenda.

For the purposes provided in Article 1.5.(g) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC, the report on the abovementioned capital increase, setting out the number and nature of the new shares to be issued in the capital increase and the reasons for and details of the offer, as well as the planned timetable for the transaction, is attached hereto.

Madrid, 8 January 2026.- The chairman of the board of directors, Mr. Manuel Manrique Cecilia.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.



## **INFORMATION DOCUMENT**

### **CAPITAL INCREASE BY SACYR, S.A. CHARGED TO RESERVES**

**8 January 2026**

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

## INFORMATION DOCUMENT

### CAPITAL INCREASE BY SACYR, S.A. charged to reserves

---

#### 1. Object

##### 1.1 Background

The ordinary general meeting of shareholders of Sacyr, S.A. (the “**Company**”) held on 12 June 2025, at second call, resolved, under item twelfth of its agenda, to increase share capital, with a charge to profits or reserves (“scrip dividend”), by a maximum nominal amount of up to 24,000,000 euros through the issuance and putting into circulation of new ordinary shares of the same class and series and carrying the same rights as the shares currently in circulation, with a nominal value of 1 euro per share and without a share premium, represented by book entries, delegating authority to execute the increase to the board of directors, with express authority to subdelegate, within a period of one year counting from the date of that meeting (the “**Capital Increase**”).

Exercising the authority granted by the ordinary general meeting of shareholders, the company’s board of directors, at its meeting held on 18 December 2025, resolved to set most of the terms and conditions and delegate to the chairman of the board of directors (with express power to subdelegate) the authority to set the rest of the terms and the conditions of the Capital Increase, including the date of execution thereof.

Accordingly, the chairman of the board of directors, exercising the authority delegated to him, today, 8 January 2026, decided to put the Capital Increase into effect, setting the remaining terms and conditions of the Capital Increase not approved by the Company’s board of directors at its meeting on 18 December 2025.

##### 1.2 Object

This information document (the “**Information Document**”) is issued for the purpose specified in Article 1.5.(g) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC, according to which the preparation and publication of a prospectus for the admission to trading of the new shares of the Company issued in the Capital Increase is not required “*provided those new shares are of the same class as the shares that have already been admitted to trading on the same regulated market and a document containing information on the number and nature of the shares and the reasons for and details of the offer is available.*”

The Information Document is available on the website of the *Comisión Nacional del Mercado de Valores* ([www.cnmv.es](http://www.cnmv.es)) and on the corporate website of the Company ([www.sacyr.com](http://www.sacyr.com)).

#### 2. Reasons for the Capital Increase

The current state of the capital markets makes it advisable for companies to maintain their capital and cash structure. However, that fact should not prevent them from meeting one

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

of their main obligations to their shareholders, which is the possibility of paying dividends, if they have the means to do so.

Thus, one of the trends in shareholder remuneration among Ibex-35 companies has been the use of flexible remuneration or "scrip dividend" schemes. Implemented through capital increases via capitalization of profits or reserves, with a commitment by the company to purchase the free allocation rights, these schemes give shareholders a choice between receiving cash or an allotment of shares of the company, subject to the tax treatment applicable to bonus shares.

With these scrip dividend schemes:

- (i) Shareholders are remunerated insofar as, if they so choose, they may sell their free allocation rights on the market or to the company itself (which assumes a firm commitment to buy them).
- (ii) The company is able to maintain its capital structure (to a greater extent than if the dividend were paid in cash), insofar as some shareholders may elect to hold their rights and not sell them to the company.

With the Capital Increase, the shareholders of the Company are offered the possibility of receiving cash remuneration, if they so wish, or shares of the Company or a combination of both.

### **3. Details of the Capital Increase**

#### **3.1 How it works**

Under the terms of the Capital Increase, shareholders of the Company will receive one free allocation right for every share of the Company they hold. These free allocation rights will be negotiable and so may be offered for sale on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges for a period of fifteen calendar days from the dealing day following the day of publication of the announcement of the Capital Increase in the Official Gazette of the Commercial Registry (BORME).

After the rights trading period, the free allocation rights will be automatically converted into newly issued shares of the Company, which will be allotted to the holders of a certain number of free allocation rights.

Therefore, in the Capital Increase, shareholders of the Company will have three options:

- (a) Not to sell their free allocation rights. In this case, at the end of the trading period, the shareholders will receive, completely free of charge, a number of new shares in proportion to their existing shareholding.
- (b) To sell all or some of their free allocation rights received from the Company to the Company, which has undertaken to purchase the rights at a guaranteed fixed price, as detailed in section 3.3 of this Information Document. In this case, shareholders will monetize their rights, receiving cash in place of shares.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

- (c) To sell all or some of their free allocation rights on the market. In this case, shareholders will also monetize their rights but will not receive a guaranteed fixed price, as the consideration for the rights will depend on market conditions in general and the quoted price of the free allocation rights in particular.

Furthermore, shareholders of the Company will be free to elect to combine any of the options described in the three sections above.

Shareholders who do not notify their election will receive the number of new shares to which they are entitled under the terms of the Capital Increase.

### **3.2 Maximum number of new shares to be issued, number of free allocation rights needed to receive one new share and maximum nominal amount of the Capital Increase**

The maximum number of new shares of the Company to be issued in execution of the Capital Increase has been set at 9,960,722, so that the maximum nominal amount of the Capital Increase is 9,960,722.00 euros.

Applying the arithmetic operations specified in the formulas approved by the ordinary s, the terms and conditions of the Capital Increase have been determined as follows.

- (i) Maximum number of new shares to be issued

The maximum number of new shares of the Company to be issued in execution of the Capital Increase is 9,960,722, so the maximum nominal amount of the Capital Increase is 9,960,722.00 euros, calculated by multiplying the maximum number of new shares to be issued by 1 euro, which is the nominal value per share.

However, the number of shares actually issued in the Capital Increase may be lower, as it will depend on the number of shareholders who elect to sell their free allocation rights. The Company will waive its right to the new shares corresponding to any free allocation rights it may acquire under the irrevocable purchase commitment stated in section 3.3 below of this Information Document and so only new shares corresponding to free allocation rights not acquired by the Company in compliance with that commitment will be issued.

In any event, the final number of shares issued in the Capital Increase will be reported in due course through a significant event notice.

The new shares will be represented by book entries and will be governed by the securities market regulations, the share register being kept by Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear) and its participants.

- (ii) Number of free allocation rights needed to receive one new share

Under the formula approved by the ordinary general meeting, the number of free allocation rights needed in order to receive one new share of the Company will be equal to the result of dividing (i) the number of shares of the Company outstanding at the date of the Capital

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

Increase execution resolution (that is, today, 8 January 2026) by (ii) the number of new shares to be issued in the Capital Increase (rounded, if the result is not a whole number, to the nearest whole number and, if the result is exactly halfway between two whole numbers, rounded up to the larger number).

The number of shares of the Company outstanding at the date of the Capital Increase execution resolution by the chairman of the board of directors (that is, today, 8 January 2026) is 796,857,798 and the maximum number of new shares to be issued in the Capital Increase, as indicated in section (i) above, is 9,960,722.

Consequently, the number of free allocation rights needed to receive one new share of the Company is 80. Each share of the Company entitles the holder to one free allocation right. In order to ensure that the number of new shares to be issued in the Capital Increase maintain exactly the proportion of one new share for every 80 shares outstanding, the Company waives its right to 38 free allocation rights corresponding to own shares held in treasury.

Shareholders of the Company who have acquired shares of the Company by the date of publication of the announcement of the Capital Increase in the Official Gazette of the Commercial Registry, which is expected to be 12 January 2026, will receive one free allocation right for every share of the Company they hold. Therefore, each such shareholder will be entitled to receive one new share for every 80 old shares held at that date.

(iii) Maximum nominal amount of the Capital Increase

The maximum nominal amount of the Capital Increase is 9,960,722.00 euros.

As already indicated, however, the amount by which the Company’s share capital will actually increase will be the result of multiplying the number of shares finally issued by their nominal value, that is, 1 euro.

As indicated above, in order to ensure that the number of free allocation rights needed in order to receive one new share and the number of new shares issued in the Capital Increase are whole numbers, the Company waives its right to 38 free allocation rights corresponding to 38 own shares held in treasury.

### 3.3 Irrevocable purchase commitment

The fixed price at which the Company irrevocably undertakes to acquire each free allocation right will be 0.049 euros gross per right, the amount yielded by the formula approved by the general meeting of shareholders shown below (rounding the result up or down to the nearest thousandth of a euro and, in the event of half a thousandth of a euro, up to the nearest thousandth of a euro):

$$\text{Purchase Price} = \frac{((\text{Quoted Price} * \text{NSCirc}) / (\text{NSCirc} + \text{NNS}))}{\text{FAR}}$$

Where:

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

- **Quoted price:** the arithmetic mean of the weighted average price at which the Company’s shares are traded on the Bilbao, Madrid, Barcelona and Valencia Stock Exchanges through the Sistema de Interconexión Bursátil (Continuous Market) on the five dealing days preceding the date of the Capital Increase execution resolution (that is, on 31 December 2025 and 2, 5, 6 and 7 January 2026), which is 3.9910 euros per share.
- **NSCirc:** the number of shares of the Company outstanding at the date of the Capital Increase execution resolution (that is, today, 8 January 2026), which is 796,857,798.
- **NNS:** the maximum number of new shares to be issued based on the set amount of the Capital Increase (which is 9,960,722, as indicated in section 3.2 above).
- **FAR:** the number of free allocation rights needed in order to receive one new share (which is 80, as indicated in section 3.2 above).

Therefore:

$$\text{Purchase price} = ((3.9910 * 796,857,798) / (796,857,798 + 9,960,722)) / 80 = \\ 0.049 \text{ euros (result rounded to the nearest thousandth of a euro)}$$

Consequently, shareholders who are so entitled and who elect to sell will be able to sell their free allocation rights to the Company at a fixed price of 0.049 euros gross per right.

The purchase commitment extends solely to allocation rights received free of charge by shareholders of the Company and not to free allocation rights purchased or otherwise acquired on the market.

This purchase commitment will be in effect and open to acceptance for a period of ten calendar days, from 13 January 2026 to 22 January 2026, inclusive, in accordance with the estimated timetable for the Capital Increase established in section 4.1 below.

The acquisition of free allocation rights by the Company under the purchase commitment will be carried out entirely against profits or reserves, as stipulated in article 303.1 of the Corporate Enterprises Act.

#### **4. Details of the execution of the Capital Increase**

##### **4.1 Tentative timetable**

The tentative timetable for execution of the Capital Increase is as follows:

8 January 2026

Filing, in another relevant notice, of this information document, which among other things will contain information on the number and nature of the new shares, the number of free allocation rights needed in order to receive one new share and the price of the rights purchase commitment to be assumed by the Company.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

12 January 2026	Publication of the announcement of execution of the Capital Increase in the Official Gazette of the Commercial Registry (BORME).
	Last day of trading of the shares of the Company, that entitle their holders to participate in the Capital Increase (“last trading date”).
13 January 2026	Date from which the shares of the Company are traded without the right to participate in the Capital Increase (“ex-date”).
	Start of the period for trading of the free allocation rights and of the period for submission of requests for cash remuneration under the rights purchase commitment assumed by the Company.
22 January 2026	End of period for submission of requests for cash remuneration under the rights purchase commitment assumed by the Company.
27 January 2026	End of the rights trading period.
29 January 2026	Payment in cash to shareholders who elected to receive cash under the rights purchase commitment assumed by the Company.
30 January 2026	Estimated date of execution and delivery of the deed of Capital Increase.
18 February 2026	Estimated date for the start of ordinary trading of the new shares on the Spanish stock exchanges.

The above timetable is tentative insofar as it is subject to compliance with deadlines and receipt of the necessary authorizations and registrations, which is beyond the Company’s control.

#### **4.2 Allocation of the free allocation rights and procedure for electing whether to receive cash or new shares**

The free allocation rights will be allocated to shareholders of the Company who have acquired their shares by the day of publication of the announcement of the Capital Increase in the Official Gazette of the Commercial Registry, which is expected to be 12 January 2026. The allocation will be made in accordance with the applicable rules, systems and procedures for securities clearing and settlement.

The free allocation rights will be transferable on the same terms as the shares from which they derive and may be traded on the market. The rights trading period on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges through the Sistema de Interconexión Bursátil (Continuous Market) will start on the dealing day following the date of

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

publication of the announcement of the Capital Increase in the Official Gazette of the Commercial Registry (that is, on 12 January 2026) and will continue for fifteen calendar days (that is, from 13 January 2026 to 27 January 2026, all inclusive). No extension of this period will be permitted.

During the rights trading period, holders of free allocation rights will be able to elect to receive new shares of the Company or an amount equivalent to the fixed and guaranteed purchase price to which they are entitled on the terms indicated above, or to acquire free allocation rights in the market in sufficient quantity and in the necessary proportion to be able to subscribe for new shares. However, holders of free allocation rights who wish to accept the irrevocable commitment to purchase those rights assumed by the Company on the terms indicated above and thus receive a cash amount equivalent to the fixed and guaranteed purchase price to which they are entitled must notify the custodian of their shares accordingly. The purchase commitment extends solely to allocation rights received free of charge by shareholders of the Company and not to free allocation rights purchased or otherwise acquired on the market.

In order to exercise their right to choose among the options offered by the Company in the Capital Increase, holders of free allocation rights must notify the custodians of the shares within the applicable deadlines, in accordance with the timetable included in section 4.1 above of this Information Document. If no express notification is given, shareholders will receive, completely free of charge, the number of new shares to which they are entitled in proportion to their existing shareholding<sup>1</sup>.

Once the rights trading period has ended, the new shares will be allocated, in the appropriate proportion, to those who, according to the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear) and its participants, hold free allocation rights.

#### **4.3 Expenses and fees**

The Capital Increase will be free of expenses and fees in respect of the allocation of the new shares issued. The Company will bear the costs of issue, subscription, putting into circulation, admission to trading and other costs related to the Capital Increase.

Nevertheless, the shareholders of the Company should bear in mind that the participants of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear) with which they have deposited their shares may, under applicable law and the terms of any securities deposit and administration agreement that may have been entered into, charge such fees and administrative expenses as they may

---

<sup>1</sup> Once the rights trading period has ended, a rights holder may hold a number of rights which, under the calculation formulas described in this Information Document, does not entitle him or her to receive a whole number of shares. In that case, the custodian of the free allocation rights may sell the number of rights that result in a fraction of a new share, so that the holder receives the proceeds of that sale in cash and does not lose the intrinsic value of those rights. However, this possibility is subject to the terms and conditions of the custody and administration agreement with the custodian in question or any instructions the holder of the rights may have given to the custodian.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

freely determine for holding the securities in their book-entry registries. Likewise, Iberclear participants may, under applicable law and the terms of any securities deposit and administration agreement that may have been entered into, pass on such fees and expenses as they may freely determine for the processing of orders to buy and sell free allocation rights.

## 5. Tax matters

The following is a brief description of the tax regime applicable in Spain under current Spanish law to the various options available to shareholders. This description does not constitute tax advice and does not include any tax considerations that may be relevant to a shareholder in light of his particular circumstances. In particular, it does not detail the consequences that may arise in their countries of residence for shareholders who are not resident in Spain for tax purposes. Shareholders should therefore consult their tax advisers on the specific tax impact of the "flexible dividend", taking into account the particular circumstances of each shareholder or holder of free assignment rights, and that they pay attention to any changes that may occur, both in the legislation in force at the date of this information document and in its interpretation criteria.

### 5.1 Shareholders without a permanent establishment in Spain who are IRPF or IRNR taxpayers

The tax regime applicable to shareholders who are subject to Spanish personal income tax (*Impuesto sobre la Renta de las Personas Físicas*, “**IRPF**”) and Spanish Non-Resident Income Tax (*Impuesto sobre la Renta de no Residentes*, “**IRNR**”), provided they do not act through a permanent establishment in Spain, would be as follows:

- (i) In the event that they receive new shares that are fully paid up as a result of the Capital Increase, shareholders will not receive any income and therefore no withholding or prepayment will be made.

The acquisition value for these shareholders, both of the new shares received as a result of the Capital Increase and the shares from which they derive, will be the result of dividing the total acquisition cost by the number of shares, including both the old shares and the corresponding paid-up shares. The holding period of the paid-up shares will be the holding period of the shares from which they derive. Consequently, in the event of a subsequent transfer, the taxable income obtained will be calculated by reference to this new acquisition value.

- (ii) In the event that shareholders sell their free allocation rights on the market, the income obtained from such transfer follows the regime established by tax regulations for the transfer of pre-emptive subscription rights, giving rise to the corresponding capital gain or loss, which is accrued in the tax period in which the transfer occurs. This is without prejudice to the potential application to IRNR taxpayers without a permanent establishment in Spain of international agreements, including agreements to avoid double taxation and prevent tax evasion in the field of income tax signed by Spain and to which they may be entitled, and the exemptions established in the IRNR regulations.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

The amount obtained from the transfer of the free allocation rights by shareholders who are IRPF taxpayers will be subject to deduction of IRPF at source at the rate applicable at that time (currently at a rate of 19%).

This IRPF will be deducted at source by the relevant depositary entity or else by the financial intermediary or notary public who facilitated the transfer of the rights. Shareholders are therefore advised to contact the appropriate depositary institutions for this purpose.

- (iii) In the event that they make use of the irrevocable purchase commitment by the Company and receive effective remuneration, since it has been made from reserves, the tax regime applicable to the amount obtained will be equivalent to the regime applicable to a distribution of cash dividends and therefore they will be subject to the corresponding withholding tax (currently, at a rate of 19%) All of this is without prejudice to the potential application to IRNR taxpayers without a permanent establishment in Spain of international agreements, including the agreements to avoid double taxation and prevent tax evasion in the field of income tax signed by Spain and to which they may be entitled, and of the exemptions established in the IRNR regulations.

## **5.2 Shareholders with a permanent establishment in Spain who are IS and IRNR taxpayers**

These shareholders must account for the capital increase in accordance with the ICAC Resolution of 5 March 2019 (the “**ICAC Resolution**”) or in accordance with their own industry standards, given that the applicable tax regulations do not contain a specific criterion for this purpose.

In order to clarify the possible tax implications of the aforementioned resolution, the Company submitted a binding tax consultation to the Directorate General of Taxes (“**DGT**”), which was completed on 20 July 2020 (reference number V2468-20). The DGT has also issued several binding consultations (reference numbers V1357-20, V1358-20, V1809-20 and V2512-20) in which it clarifies both the accounting regime (through clarifications made by the ICAC to the DGT) and the tax regime applicable following the ICAC Resolution (together with the consultation submitted by the company, the “**Tax Consultations**”).

In accordance with the aforementioned consultations and taking into account that both the attribution of the rights of free allocation of the “flexible dividend” redeemable on the market or capable of being acquired by the Company, as well as the increase in freed-up capital will be carried out with a charge to reserves corresponding to undistributed profits, the income obtained by the shareholder will be classified as a dividend. With effect from any tax period initiated on 1 January 2021, this income will be exempted in a 95 per cent. in the taxable income provided that the requirements of article 21.1 LIS<sup>2</sup>

---

<sup>2</sup> The requirements for applying the exemption included in Article 21.1 of the LIS are; percentage of participation in the capital of the entity is at least 5%; on a transitional basis, the exemption also applies until 31-12-2025 to holdings acquired in tax periods commencing prior to 1 January 2021 and having an acquisition value of more than 20 million euros, without reaching the aforementioned percentage of 5%. The holding must be held without interruption during

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

are met. Otherwise, such income shall be included in the tax base. All of this is independent of the option chosen by the shareholder: to receive freed up shares, to sell free assignment rights on the market or to resort to the irrevocable purchase commitment by the Company.

Likewise, no withholding or payment on account shall be made by the Company in any of the cases, unless the dividends result from the sale of free assignment rights to the Company and article 21.1 LIS is not applicable to the shareholder.

It should be noted that this tax regime analysis does not set out all the possible tax consequences of the various options related to the implementation of the Capital Increase. In particular, it does not detail the consequences that can be produced in their countries of residence for those shareholders who are not residents in Spain for tax purposes. It is therefore recommended for shareholders or holders of free allocation rights to consult their tax advisers on the specific tax impact of the proposed remuneration system, taking into account their respective specificities, and to pay attention to the modifications that may occur both in the legislation in force at the date of this Information Document as well as in its interpretation criteria.

### **5.3 Financial Transactions Tax (*Impuesto sobre Transacciones Financieras*)**

On 7 October 2020, the Law on the Tax on Financial Transactions (the “**LITF**” and the “**ITF**”, respectively) was adopted, and later published in the Official State Gazette (“**BOE**”) on 16 October 2020. The ITF will enter into force three months after its publication in the BOE (that is, on 16 January 2021). In accordance with the terms of the LITF, the ITF levies a fixed rate of 0.2% on onerous share acquisitions of Spanish companies that are admitted to trading on a Spanish market, a regulated market in the European Union or a market considered to be equivalent in a third country, provided that the capitalization value of the company at 1 December of the year prior to the acquisition is over 1,000 million euros.

In accordance with the provisions of the LITF, the State Tax Administration Agency has published a list of Spanish companies whose shares, as of 1 December 2025, have a market capitalisation value of more than €1 billion. The Company is included in this list, which means that, in principle, any onerous acquisitions of its shares (or of the deposit certificates representing those shares, such as ADRs or CDIs) throughout 2025 would fall within the scope of the ITF (without prejudice to any applicable exemptions).

That said, the State Tax Administration Agency has published a document entitled “Frequently Asked Questions on Financial Transaction Tax” (which is updated periodically), according to which acquisitions of shares under shareholder remuneration

---

the year preceding the day on which the profit to be distributed falls due or, failing that, must be maintained thereafter for the time necessary to complete that period.

In the case of entities not resident in Spanish territory, the investee entity must have been subject to and not exempt from a foreign tax of an identical or similar nature to the IS at a nominal rate of at least 10%. When the investee entity is resident in a country with which Spain has signed an agreement to avoid international double taxation, which contains an exchange of information clause, this requirement will be deemed to have been met.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

programmes known as "scrip dividends" (to the extent that the shares delivered are new shares resulting from a fully paid-up capital increase) are not subject to ITF.

However, the FTT could subject other transactions involving the Company's shares (or ADRs or CDIs) to taxation (at a fixed rate of 0.2%), regardless of the residence of the parties involved.

In any case, shareholders and holders of free allocation rights are advised to consult their tax advisers on the impact of these tax measures (in particular the implementation of the ITF), taking into account the particular circumstances of each shareholder or holder of free allocation rights.

## **6. Number and nature of the new shares to be issued**

### **6.1 Nominal value, representation and issue price of the new shares**

The new shares issued in the Capital Increase will be ordinary shares with a nominal value of 1 euro per share, of the same class and series as the shares currently outstanding, represented by book entries in registers kept by Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear) and its participants.

The new shares will be issued at par, without a share premium, which means that their issue price will be their nominal value, and will be allocated to shareholders free of charge on the terms indicated above.

### **6.2 Rights conferred by the new shares**

From the date the Capital Increase is announced to have been subscribed and paid in, the new shares will confer upon their holders the same voting rights as, and will rank pari passu with, the ordinary shares of the Company currently outstanding.

### **6.3 Consideration and balance sheet for the Capital Increase**

The Capital Increase does not entail any payment by shareholders of the Company. The payment will be made entirely out of unrestricted reserves held in the voluntary reserves account.

The balance sheet used as the basis for the Capital Increase is that for the year ended 31 December 2024, which was duly audited by the Company's auditors and approved by the ordinary general meeting of shareholders on 12 June 2025 as the first item of business on the agenda.

### **6.4 Shares in deposit**

Once the rights trading period has ended, any new shares, which, once issued, have not been allocated for reasons not attributable to the Company will be held in deposit at the disposal of any person who is able to prove legitimate ownership of the necessary free allocation rights.

Informative English version of the “*Documento Informativo*” drafted in Spanish. In case of discrepancy the Spanish version will prevail.

After three years have elapsed since the end of the abovementioned rights trading period, any shares still unallocated may be sold pursuant to article 117 of the Corporate Enterprises Act, at the expense and risk of the interested parties. Any cash proceeds from such sale will be deposited at the Bank of Spain or the General Deposit Fund (*Caja General de Depósitos*) at the disposal of the interested parties.

#### **6.5 Application for admission to trading**

The Company will make application for the admission to trading of the new shares issued in the Capital Increase on the Bilbao, Madrid, Barcelona and Valencia stock exchanges, through the Sistema de Interconexión Bursátil (Continuous Market), and will take such steps and submit such documents as may be necessary to ensure that the new shares are effectively admitted to trading, expressly acknowledging that the Company remains subject to any existing or possible future rules governing the securities market, especially as regards trading, continued trading and withdrawal from trading.

Madrid, 8 January 2026.

For Sacyr, S.A.

Mr. Manuel Manrique Cecilia  
Chairman of the board of directors